Minimally Invasive Glaucoma Surgery Devices Market - Global Forecast 2025-2030

The minimally invasive glaucoma surgery devices market is rapidly evolving, driven by technological innovation, shifting clinical priorities, and changing dynamics in care delivery. Senior decision-makers are increasingly focused on streamlining workflows, optimizing outcomes, and adapting to global supply chain pressures in this competitive landscape.

Market Snapshot: Minimally Invasive Glaucoma Surgery Devices Market Overview

The minimally invasive glaucoma surgery devices market grew from USD 585.26 million in 2024 to USD 618.15 million in 2025 and is projected to maintain a compound annual growth rate (CAGR) of 5.76%, reaching USD 819.46 million by 2030. This expansion is propelled by advances in surgical techniques, a heightened focus on patient safety and staff efficiency, and the introduction of technologically sophisticated implants seamlessly fitting modern clinical workflows. Increasing adoption of these devices is reinforced by the need for effective interventions that improve patient outcomes while supporting operational priorities.

Scope & Segmentation of Minimally Invasive Glaucoma Surgery Devices

This report delivers detailed market segmentation and analysis, enabling strategic planning and nuanced decision-making for stakeholders across the value chain:

• Device Types: Includes ablation tools, catheters, lumen-based shunts (fixed-lumen, flow-controlled), scaffolds and expanders, and stents, each tailored to varying clinical requirements and procedural needs.
• Surgical Sites: Covers interventions targeting the ciliary body, Schlemm’s canal, subconjunctival space, suprachoroidal space, and trabecular meshwork, addressing the anatomical complexities of glaucoma management.
• Indications: Encompasses devices indicated for angle-closure glaucoma, congenital glaucoma, primary open-angle glaucoma, and secondary forms, ensuring comprehensive market evaluation across the full clinical spectrum.
• Surgical Approaches: Solutions support both ab externo and ab interno surgical techniques, allowing for procedural flexibility within various practice settings.
• Procedure Types: Includes options for combined cataract surgery and standalone glaucoma procedures, responding to the diverse practice patterns of ophthalmic specialists.
• Implant Materials: Utilizes metals (such as nitinol and titanium) and a range of polymers (gelatin, polyethersulfone, polyimide, silicone) that meet specific biocompatibility and performance criteria.
• Device Classes: Spans both implantable and non-implantable products, providing a foundation for procedure-specific selection and customization.
• End Users: Addresses demand in ambulatory surgery centers, ophthalmic clinics, and specialty eye hospitals, ensuring coverage of the principal points of care.
• Distribution Channels: Considers both offline and online channels, reflecting the growing influence of digital platforms in procurement and product delivery.
• Regions Covered: Offers insights for the Americas (North America, Latin America), Europe, Middle East & Africa, and Asia-Pacific, with precise country-level analysis in both established and emerging markets.
• Companies Profiled: Evaluates strategies of leading and new device manufacturers, highlighting incremental innovation and the importance of adaptive partnership models.

Key Takeaways for Decision-Makers

• Clinical workflows now emphasize earlier and less invasive surgical intervention, aligning with evolving patient and provider expectations for manageable procedures and sustained quality of life improvements.
• Innovation in modular device platforms is enabling surgical teams to select and combine implants more flexibly, which accommodates complex patient presentations and is compatible with combined anterior segment procedures.
• The role of digital diagnostics and artificial intelligence is expanding, supporting earlier detection, more precise patient selection, and the need for adaptable implant delivery systems to serve diverse populations.
• Strategic sourcing and supply chain diversification, driven by tariff-related and regulatory pressures, are prompting companies to invest in regional manufacturing and localized supplier partnerships.
• Real-world evidence and robust outcome data are fundamental for demonstrating device value, supporting successful reimbursement strategies and facilitating broader adoption in diverse health systems.
• Differences in payer arrangements, clinical training infrastructure, and procurement processes across regions underscore the importance of tailored engagement and data-driven market entry or expansion strategies.

Tariff Impact on Strategic Decisions

Recent United States tariff adjustments have led manufacturers to reevaluate sourcing, supplier portfolios, and material choices. The resulting strategies include qualifying new domestic suppliers, exploring alternative materials, and accelerating localized production to offset procurement cost fluctuations. Health systems are accordingly adapting acquisition decisions and scenario planning to manage long-term value in light of these supply chain impacts.

Research Methodology & Data Sources

The report’s methodology integrates direct interviews with clinicians, procurement leaders, and industry executives, complemented by secondary research from reputable publications, regulatory archives, and policy reviews. Data triangulation and scenario analysis ensure comprehensive, reliable insights that account for geographic differences in market practice and regulatory shifts.

Why This Report Matters for Senior Decision-Makers

• Empowers strategic planning through detailed segmentation, technology analysis, and region-specific insights aligned with unique reimbursement and operational environments.
• Supports data-driven investment and supplier decisions, underpinned by validated outcomes and in-depth, real-world evidence of evolving clinical needs.
• Equips leaders to address emerging risk, tailored procurement, and evolving clinical pathways by integrating flexible supply and market strategies.

Conclusion

The minimally invasive glaucoma surgery devices market is positioned for ongoing transformation as new clinical requirements, technology advances, and changing regulatory conditions influence procurement and strategy. Forward-thinking stakeholders who prioritize evidence-based approaches and regional alignment will be best positioned for sustained growth.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.